Thursday, January 25, 2018 11:35:50 AM
The contest winner lost a total of 80 pounds, or 41% total weight loss (TWL), with 60 pounds, or 28% TWL, lost during the 6-month ReShape Balloon implant period, followed by continued weight loss of the remaining 20 pounds after device removal. The patient, a female, age 53, had the ReShape Balloon placed by Dr. Vivek Kumbhari, MD, Director of Endoscopy at Johns Hopkins Bayview Medical Center & Director of Bariatric Endoscopy at Johns Hopkins Weight Management Center.
The second and third place winners, a 39-year-old male and a 33-year-old female, had 6-month TWL of 25% and 21%, respectively.
"In my experience, the ReShape Balloon has been a safe and effective option for patients who have failed diet and exercise and who are either not indicated for or are afraid of surgical solutions," commented Dr. Kumbhari. "We have found that the ReShape program, which includes the six-month dual balloon implant coupled with diet, exercise and monthly behavior modification coaching, has helped patients lose significant weight, while often also improving related comorbidities such as high blood pressure and high cholesterol."
The ReShape Balloon is the only FDA-approved dual balloon that is designed to help people lose weight by taking up room in the stomach, thereby helping people feel full and eat less. The balloon is inserted in a single visit and is designed to stay in the stomach for up to six months
Read more about ReShape success stories at: https://reshapeready.com/success-stories/
About ReShape Lifesciences Inc.
ReShape Lifesciences is a medical device company focused on technology to treat obesity and metabolic diseases. The FDA-approved ReShape BalloonTM involves a non-surgical weight loss procedure that uses advanced interconnected balloon technology designed to take up room in the stomach to help people with a 30-40 BMI, and at least one co-morbidity, lose weight. ReShape vBlocTM Neurometabolic Therapy, delivered by an FDA-approved pacemaker-like device called the vBloc System, is designed to help patients with a Body Mass Index (BMI) of 40-45, or 35-39.9 with a minimum of one related comorbid condition, feel full, eat less and lose weight by intermittently blocking hunger signals on the vagus nerve. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others: risks and uncertainties related to our acquisition of ReShape Medical, Inc., including unexpected costs or liabilities, the ability to recognize the benefits of the acquisition and that the acquisition may involve unexpected costs or liabilities; our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience with our vBloc® System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; the competitive industry in which we operate; our ability to maintain compliance with the Nasdaq continued listing requirements; our ability to commercialize our vBloc System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our vBloc System; physician adoption of our vBloc System and vBloc Neurometabolic Therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; the cost and management time of operating a public company; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in Exhibit 99.3 of our current report on Form 8-K filed July 26, 2017. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
ReShape Lifesciences Inc. logo
Cision View original content with multimedia:http://www.prnewswire.com/news-releases/reshape-lifesciences-announces-2017-weight-loss-contest-winner-300588065.html
SOURCE ReShape Lifesciences Inc.
Copyright 2018 PR Newswire
Recent RSLS News
- ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/01/2024 08:05:00 PM
- ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System • GlobeNewswire Inc. • 03/28/2024 12:31:00 PM
- ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX • GlobeNewswire Inc. • 03/04/2024 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 09:19:43 PM
- ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX • GlobeNewswire Inc. • 02/22/2024 01:31:00 PM
- ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX • GlobeNewswire Inc. • 01/24/2024 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:38:03 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 11:11:06 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 01/05/2024 09:14:25 PM
- ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives • GlobeNewswire Inc. • 12/20/2023 01:31:00 PM
- ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX • GlobeNewswire Inc. • 12/12/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 09:05:16 PM
- ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds • GlobeNewswire Inc. • 11/21/2023 01:06:14 PM
- ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan • GlobeNewswire Inc. • 11/08/2023 09:05:00 PM
- ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update • GlobeNewswire Inc. • 11/06/2023 01:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 08:42:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 08:05:13 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 10/03/2023 01:23:13 PM
- ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering • GlobeNewswire Inc. • 09/29/2023 04:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/27/2023 09:30:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 08:02:52 PM
- ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI • GlobeNewswire Inc. • 09/22/2023 12:31:00 PM
- ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System • GlobeNewswire Inc. • 09/21/2023 12:31:00 PM
- ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System • GlobeNewswire Inc. • 09/19/2023 12:31:00 PM
- ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device • GlobeNewswire Inc. • 09/14/2023 12:31:00 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM